LifeArc Rare Disease Clinical Trials Programme
Supports clinical rare-disease teams with practical trial design and execution.
LifeArc is a UK-registered not-for-profit life science organisation (Charity No. 1015243) founded in 2000 as MRC Technology, which gained major endowment through the 2019 sale of rights to the cancer drug pembrolizumab (Keytruda). Its Rare Disease Clinical Trials Programme is a rolling grant facility open for applications year-round, with proposals reviewed on a continuous basis. The programme fun…
Rolling grants of up to £5 million for clinical-stage rare disease trial projects, with particular encouragement for rare neurodegenerative diseases, rare respiratory conditions, and childhood cancer.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline